National Biopharmaceutical Industry Base Leading Group Meeting Held in Shanghai

The 9th meeting of the Leading Group of the National Shanghai Biomedicine Technology Industry Base was held in Shanghai. The meeting made it clear that during the “Twelfth Five-Year Plan” period, it will focus on the construction of high-tech industrialization projects, accelerate the construction of industrial parks, and accelerate the improvement of industrial policy systems. It will continue to promote the sustained, rapid, and healthy development of the national Shanghai Biomedical Technology Industry Base. Deputy Secretary of the Shanghai Municipal Party Committee, Mayor Han Zheng, Vice Minister of Science and Technology Wang Weizhong, Deputy Minister of Health, Director of the State Food and Drug Administration Shao Mingli, Vice Minister of Health Liu Qian, Deputy Director of the Chinese Academy of Sciences Shi Erwei, Vice Dean of the Chinese Academy of Engineering Fan Daiming Waited for the meeting and spoke. Shen Xiaoming, deputy mayor of Shanghai, presided over the meeting.

In his speech, Han pointed out that biopharmaceuticals is one of the seven strategic emerging industries that Shanghai has focused on cultivating and developing. Accelerating the development of the biopharmaceutical industry is not only in line with the country's strategic positioning and requirements for Shanghai, but also the promotion of Shanghai's "12th Five Year Plan" innovation. Drive, transformation and development of important initiatives. To enhance the sense of responsibility and urgency in serving national strategies, and with the strong support of relevant national ministries and commissions, Shanghai should give full play to its advantages in the field of biomedicine, including a good foundation for innovation, great development potential, and good market prospects, and promote the leap-forward development of the biomedical industry.

Han Zheng pointed out that it is necessary to seize the opportunity, focus on the key points, and make every effort to promote the expansion of the biomedical industry in Shanghai. The development of the biopharmaceutical industry in Shanghai must be promoted in the overall strategic deployment of the country and must be promoted with the guidance, support, and assistance of the relevant national ministries and commissions. It is necessary to cultivate the industry’s independent technology system as the core, and to cultivate the main body of the enterprise as the starting point, and to take major development needs and technological breakthroughs as the driving force. With institutional innovation and policy environment as the guarantee, vigorously promote the scale, agglomeration and internationalization of the Shanghai biomedical industry. Development. In practical work, we must grasp the "three combinations", that is, to adhere to the combination of serving the national strategy and local development, to adhere to the combination of serving the people's health needs and the market mechanism, and to combine independent innovation with open cooperation. In the next step, we must implement the “Four Focuses,” namely, focusing on industrial bases, focusing on corporate innovation, focusing on industrial policies, focusing on strengthening government services, and scientific supervision. Industries involving the health of the people should be strictly regulated by the government. .

At the meeting, Director of the Leading Group Office of the National Shanghai Biomedical Science and Technology Industry Base and Director of the Shanghai Municipal Science and Technology Commission, Shouzi Qi, reported to the leading group on the progress of the construction of the national Shanghai Biomedical Science and Technology Industrial Base. Before the meeting, Sinopharm Co., Ltd. signed strategic cooperation framework agreements with Shanghai Kahr Magnetic Resonance Technology Co., Ltd. and Miele Medical Group. The governments of the six major industrial bases and 12 enterprises signed the investment agreement for the national Shanghai Biomedical Science and Technology Industrial Base.